NCT05000450: Phase 1/2: Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell RRMM

IGNITE STUDY - ALLO-605: IGNITE STUDY UTILIZING FIRST TurboCAR™ TO TARGET BCMA

NCT05000450: Phase 1/2: Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

The purpose of the ALLO-605-201 study is to assess the safety, efficacy, and cell kinetics of ALLO605 in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647.

Sponsor

Allogene Therapeutics

Locations

United States, Colorado

United States, Texas

---

ClinicalTrials.gov Identifier: NCT05000450

Official Title: A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-647 and ALLO-605, an Anti- BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

First Posted : August 11, 2021

Click here to see details on ClinicalTrials.gov

---

Genetic: ALLO-605

Biological: ALLO-647

Drug: Fludarabine

Drug: Cyclophosphamide

---

ALLO 605

Allogeneic Anti-BCMA CAR T Cells ALLO-605 (Code C182066)

ALLO 605

ALLO-605

ALLO605

Allogeneic Anti-BCMA CAR T Cells ALLO-605

Allogeneic Anti-BCMA CAR-T Cells ALLO-605

Allogeneic Anti-BCMA TRAC/CD52-edited CAR T Cells ALLO-605

Allogeneic BCMA TurboCAR T Cells ALLO-605

---

ALLO 647

Anti-CD52 Monoclonal Antibody ALLO-647 (Code C160787)

ALLO 647

ALLO-647

ALLO647

Anti-CD52 Monoclonal Antibody ALLO-647

---

Locations

United States, Colorado

United States, Texas